NASDAQ:BMRA - Biomerica Stock Price, Price Target & More

$3.57 +0.02 (+0.56 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$3.55
Today's Range$3.51 - $3.70
52-Week Range$2.30 - $9.32
Volume11,946 shs
Average Volume88,163 shs
Market Capitalization$33.05 million
P/E Ratio-32.00
Dividend YieldN/A
Beta-0.63

About Biomerica (NASDAQ:BMRA)

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BMRA
CUSIPN/A
Phone949-645-2111

Debt

Debt-to-Equity RatioN/A
Current Ratio5.39%
Quick Ratio2.79%

Price-To-Earnings

Trailing P/E Ratio-32.00
Forward P/E Ratio-21.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.79 million
Price / Sales5.33
Cash FlowN/A
Price / CashN/A
Book Value$0.46 per share
Price / Book7.76

Profitability

EPS (Most Recent Fiscal Year)($0.11)
Net Income$-900,000.00
Net Margins-19.46%
Return on Equity-27.29%
Return on Assets-23.47%

Miscellaneous

Employees39
Outstanding Shares8,650,000

How to Become a New Pot Stock Millionaire

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How were Biomerica's earnings last quarter?

Biomerica (NASDAQ:BMRA) posted its earnings results on Monday, April, 16th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. The company had revenue of $1.38 million for the quarter, compared to analyst estimates of $1.56 million. Biomerica had a negative net margin of 19.46% and a negative return on equity of 27.29%. View Biomerica's Earnings History.

What price target have analysts set for BMRA?

1 brokers have issued 12-month price targets for Biomerica's stock. Their predictions range from $7.50 to $7.50. On average, they anticipate Biomerica's stock price to reach $7.50 in the next twelve months. View Analyst Ratings for Biomerica.

Who are some of Biomerica's key competitors?

Who are Biomerica's key executives?

Biomerica's management team includes the folowing people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 52)
  • Mr. Francis E. Capitanio, Pres (Age 74)
  • Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 67)

Has Biomerica been receiving favorable news coverage?

News articles about BMRA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biomerica earned a news sentiment score of 0.05 on Accern's scale. They also assigned press coverage about the company an impact score of 47.60 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $3.57.

How big of a company is Biomerica?

Biomerica has a market capitalization of $33.05 million and generates $5.79 million in revenue each year. The company earns $-900,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Biomerica employs 39 workers across the globe.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.


MarketBeat Community Rating for Biomerica (BMRA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  81
MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe BMRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biomerica (NASDAQ:BMRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Biomerica in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 110.08%. The high price target for BMRA is $7.50 and the low price target for BMRA is $7.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$7.50N/A
Price Target Upside: 110.08% upside87.97% upside87.97% upsideN/A

Biomerica (NASDAQ:BMRA) Consensus Price Target History

Price Target History for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ:BMRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018B. RileyInitiated CoverageBuy -> Buy$7.50HighView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Biomerica (NASDAQ:BMRA) Earnings History and Estimates Chart

Earnings by Quarter for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ:BMRA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.03)($0.03)($0.03)
Q2 20182($0.04)($0.03)($0.04)
Q3 20182($0.06)($0.05)($0.06)
Q4 20182($0.08)($0.06)($0.07)

Biomerica (NASDAQ BMRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/16/2018Q3 2018($0.06)($0.0380)$1.56 million$1.38 millionViewN/AView Earnings Details
1/16/2018Q2 2018($0.04)($0.03)$1.48 million$1.61 millionViewN/AView Earnings Details
10/16/2017Q1 2018($0.03)($0.02)$1.52 million$1.44 millionViewN/AView Earnings Details
8/30/2017Q4 2017($0.02)($0.04)$1.47 million$1.45 millionViewN/AView Earnings Details
4/14/2017Q3 2017($0.03)($0.04)$1.39 million$1.50 millionViewN/AView Earnings Details
1/17/2017Q2 2017($0.03)($0.02)$1.17 million$1.43 millionViewN/AView Earnings Details
10/17/2016Q1 2017($0.03)($0.01)$1.26 million$1.41 millionViewN/AView Earnings Details
8/30/2016Q4 2016($0.01)($0.16)$1.32 million$1.33 millionViewN/AView Earnings Details
4/14/2016Q3 2016($0.02)($0.02)$1.52 million$1.36 millionViewN/AView Earnings Details
1/14/2016Q2 2016($0.02)($0.01)$1.49 million$1.17 millionViewN/AView Earnings Details
10/15/2015Q1 2016($0.02)($0.01)$1.32 million$1.29 millionViewN/AView Earnings Details
9/1/2015Q4 2015$0.03$1.42 million$1.49 millionViewN/AView Earnings Details
4/15/2015Q3 2015($0.01)($0.02)$1.50 million$1.30 millionViewN/AView Earnings Details
1/15/2015Q2 2015($0.01)($0.03)$1.40 million$1.13 millionViewN/AView Earnings Details
10/16/2014Q1 2015($0.03)($0.03)$1.24 million$1.03 millionViewN/AView Earnings Details
9/2/2014Q4 2014$0.02$0.02$1.43 million$1.68 millionViewN/AView Earnings Details
1/15/2014Nov 2013($0.01)($0.03)$1.16 million$0.94 millionViewN/AView Earnings Details
10/15/2013Q1 2014($0.02)$1.43 million$1.01 millionViewN/AView Earnings Details
8/29/2013Q4 2013$0.01$1.47 millionViewN/AView Earnings Details
4/15/2013Q3 2013$0.03($0.01)$1.77 million$1.42 millionViewN/AView Earnings Details
1/14/2013Q2 2013$0.03ViewN/AView Earnings Details
10/15/2012Q1 2013$0.04ViewN/AView Earnings Details
8/29/2012Q4 2012$0.01ViewN/AView Earnings Details
4/17/2012Q3 2012$0.03ViewN/AView Earnings Details
1/17/2012Q2 2012$0.03ViewN/AView Earnings Details
10/18/2011Q1 2012$0.02ViewN/AView Earnings Details
8/30/2011Q4 2011$0.01ViewN/AView Earnings Details
4/15/2011Q3 2011$0.01ViewN/AView Earnings Details
4/15/2010Q3 2010$0.02ViewN/AView Earnings Details
1/19/2010Q2 2010($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Biomerica (NASDAQ:BMRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biomerica (NASDAQ BMRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.30%
Institutional Ownership Percentage: 1.27%
Insider Trading History for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ BMRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Zackary S IraniCEOBuy500$3.83$1,915.00860,539View SEC Filing  
2/2/2018Zackary S IraniCEOBuy1,000$3.96$3,960.00860,039View SEC Filing  
1/25/2018Francis CanoDirectorBuy11,800$4.18$49,324.00128,036View SEC Filing  
1/25/2018Zackary S IraniCEOBuy2,039$4.03$8,217.17857,000View SEC Filing  
1/23/2018Zackary S IraniCEOBuy500$3.85$1,925.00857,000View SEC Filing  
2/27/2017Francis E CapitanioPresidentSell15,000$2.46$36,900.00102,000View SEC Filing  
1/4/2017Janet MooreCFOSell4,500$2.20$9,900.00145,220View SEC Filing  
12/22/2016Janet MooreCFOSell9,780$2.18$21,320.40142,000View SEC Filing  
12/12/2016Francis E CapitanioPresidentSell9,351$2.77$25,902.2796,351View SEC Filing  
12/8/2016Francis E CapitanioPresidentSell10,649$2.89$30,775.6190,649View SEC Filing  
11/14/2016Zackary S IraniCEOBuy400$1.94$776.00781,200View SEC Filing  
11/8/2016Zackary S IraniCEOBuy500$1.74$870.00781,000View SEC Filing  
11/4/2016Zackary S IraniCEOBuy1,000$1.95$1,950.00780,600View SEC Filing  
10/20/2016Francis E CapitanioPresidentSell10,000$2.68$26,800.0082,000View SEC Filing  
10/3/2016Jane EmersonDirectorBuy1,000$2.80$2,800.0021,000View SEC Filing  
9/7/2016Zackary S IraniCEOBuy199$2.65$527.35779,600View SEC Filing  
8/12/2016Janet MooreCFOBuy2,200$2.98$6,556.00121,000View SEC Filing  
8/12/2016Zackary S IraniInsiderBuy3,166$2.98$9,434.68776,435View SEC Filing  
8/11/2016Zackary S IraniCEOBuy3,700$2.88$10,656.00773,035View SEC Filing  
8/10/2016Zackary S IraniCEOBuy1,000$2.72$2,720.00771,935View SEC Filing  
8/9/2016Allen BarbieriDirectorBuy3,000$2.54$7,620.0099,889View SEC Filing  
8/5/2016Francis CanoDirectorBuy16,300$2.37$38,631.0082,100View SEC Filing  
8/3/2016Mark A SirgoDirectorBuy4,000$2.05$8,200.0012,000View SEC Filing  
8/3/2016Zackary S IraniCEOBuy2,609$2.10$5,478.90769,926View SEC Filing  
8/2/2016Mark A SirgoDirectorBuy8,000$1.97$15,760.002,000View SEC Filing  
8/1/2016Zackary S IraniCEOBuy5,400$1.88$10,152.00765,926View SEC Filing  
5/16/2016Francis E CapitanioPresidentSell20,000$1.50$30,000.0087,000View SEC Filing  
11/13/2015Zackary S IraniCEOBuy5,000$0.83$4,150.00711,526View SEC Filing  
6/8/2015Zackary S IraniCEOBuy3,000$1.08$3,240.00View SEC Filing  
5/22/2015Zackary S IraniCEOBuy2,000$0.85$1,700.00View SEC Filing  
5/11/2015Zackary S IraniCEOBuy18,000$0.91$16,380.00View SEC Filing  
9/6/2012Zackary S IraniCEOBuy7,000$0.70$4,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biomerica (NASDAQ BMRA) News Headlines

Source:
DateHeadline
Biomerica adds Harry Leider, MD, MBA to Strategic Advisory BoardBiomerica adds Harry Leider, MD, MBA to Strategic Advisory Board
finance.yahoo.com - April 19 at 10:01 AM
BMRA: Q3 2018 Results: Asia Remains Strong While U.S., Europe Slip. Encouraged By Robustness of InFoods Study DesignBMRA: Q3 2018 Results: Asia Remains Strong While U.S., Europe Slip. Encouraged By Robustness of InFoods Study Design
finance.yahoo.com - April 19 at 10:01 AM
Biomerica (BMRA) Releases Quarterly  Earnings Results, Beats Estimates By $0.02 EPSBiomerica (BMRA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - April 18 at 9:54 AM
Does Biomerica Inc’s (NASDAQ:BMRA) Past Performance Indicate A Stronger Future?Does Biomerica Inc’s (NASDAQ:BMRA) Past Performance Indicate A Stronger Future?
finance.yahoo.com - April 17 at 4:22 PM
Biomerica Announces Third Quarter Financial ResultsBiomerica Announces Third Quarter Financial Results
finance.yahoo.com - April 17 at 10:20 AM
Biomerica (BMRA) Downgraded to "Sell" at ValuEngineBiomerica (BMRA) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
Biomerica (BMRA) Now Covered by Analysts at B. RileyBiomerica (BMRA) Now Covered by Analysts at B. Riley
www.americanbankingnews.com - March 30 at 5:08 PM
Mexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancerMexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
finance.yahoo.com - March 8 at 10:28 AM
Biomerica Inc (NASDAQ:BMRA): Is Breakeven Near?Biomerica Inc (NASDAQ:BMRA): Is Breakeven Near?
finance.yahoo.com - March 2 at 9:51 AM
FY2018 Earnings Estimate for Biomerica, Inc. Issued By B. Riley (BMRA)FY2018 Earnings Estimate for Biomerica, Inc. Issued By B. Riley (BMRA)
www.americanbankingnews.com - February 9 at 1:43 PM
Francis Cano Acquires 11,800 Shares of Biomerica, Inc. (BMRA) StockFrancis Cano Acquires 11,800 Shares of Biomerica, Inc. (BMRA) Stock
www.americanbankingnews.com - January 25 at 9:44 PM
Zacks Investment Research Weighs in on Biomerica, Inc.s Q3 2018 Earnings (BMRA)Zacks Investment Research Weighs in on Biomerica, Inc.'s Q3 2018 Earnings (BMRA)
www.americanbankingnews.com - January 25 at 11:28 AM
BMRA: Moving Price Target to $7/Share With Inclusion of InFoodsBMRA: Moving Price Target to $7/Share With Inclusion of InFoods
finance.yahoo.com - January 23 at 4:26 PM
Biomerica, Inc. :BMRA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 19, 2018Biomerica, Inc. :BMRA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 19, 2018
finance.yahoo.com - January 19 at 6:21 PM
Biomerica (BMRA) Releases Quarterly  Earnings Results, Beats Expectations By $0.01 EPSBiomerica (BMRA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - January 17 at 1:34 PM
Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the QuarterBiomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter
finance.yahoo.com - January 16 at 5:37 PM
Biomerica, Inc. (BMRA) Announces China FDA Approval of Colorectal Screening Test to help Identify Early Warning Signs of Colorectal CancerBiomerica, Inc. (BMRA) Announces China FDA Approval of Colorectal Screening Test to help Identify Early Warning Signs of Colorectal Cancer
www.streetinsider.com - January 11 at 9:23 AM
BRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal CancerBRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer
www.reuters.com - January 10 at 5:39 PM
China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancerChina Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer
finance.yahoo.com - January 10 at 9:11 AM
Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success?
finance.yahoo.com - January 9 at 9:10 AM
Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT)
finance.yahoo.com - January 8 at 5:50 PM
Q2 2018 Earnings Estimate for Biomerica, Inc. (BMRA) Issued By B. RileyQ2 2018 Earnings Estimate for Biomerica, Inc. (BMRA) Issued By B. Riley
www.americanbankingnews.com - January 8 at 6:38 AM
Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - January 2 at 9:06 AM
Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer?
finance.yahoo.com - December 25 at 7:19 PM
What You Must Know About Biomerica Inc’s (BMRA) Financial HealthWhat You Must Know About Biomerica Inc’s (BMRA) Financial Health
finance.yahoo.com - December 7 at 6:13 PM
BRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBRBRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBR
www.reuters.com - December 4 at 9:01 AM
Biomerica (BMRA) Cut to Sell at ValuEngineBiomerica (BMRA) Cut to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 9:26 PM
Biomerica Announces Enrollment of First Patient for H. Pylori Clinical Studies at the University of Southern CaliforniaBiomerica Announces Enrollment of First Patient for H. Pylori Clinical Studies at the University of Southern California
finance.yahoo.com - November 20 at 5:50 PM

SEC Filings

Biomerica (NASDAQ:BMRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biomerica (NASDAQ:BMRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biomerica (NASDAQ BMRA) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.